15.65
-0.55 (-3.40%)
| Previous Close | 16.20 |
| Open | 16.11 |
| Volume | 420,414 |
| Avg. Volume (3M) | 549,430 |
| Market Cap | 945,275,648 |
| Price / Sales | 650.22 |
| Price / Book | 3.42 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -1.5 |
| Average | -2.40 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURROWS SCOTT L | - | 16.63 | -18,428 | -306,458 |
| Aggregate Net Quantity | -18,428 | |||
| Aggregate Net Value ($) | -306,458 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.63 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BURROWS SCOTT L | Officer | 02 Sep 2025 | Sell (-) | 18,428 | 16.63 | 306,458 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |